CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 204 enrolled
Drug / intervention
DaTscan™ - Non-Caucasian Participants +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01952678
NCT01952678N/ACompleted
CompareCT.gov

A Retrospective Clinical Study to Compare the Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

GE Healthcare·observational·Posted Sep 30, 2013·Updated Aug 2, 2018

In Brief

An observational study evaluating DaTscan™ - Non-Caucasian Participants and DaTscan™ - Caucasian Participants for Essential Tremor and Parkinson's Disease. Completed, enrolled 204 participants across 1 site.

Detailed Summary

The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with movement disorders.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor, Parkinson's Disease
CountriesUnited States
CollaboratorsH2O Clinical LLC, Quintiles, Inc.

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 30, 2013
Enrollment StartJul 30, 2013
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.8 years ago

Interventions

DaTscan™ - Non-Caucasian Participantsother

Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.

DaTscan™ - Caucasian Participantsother

Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.